Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
LTBP4 Biologics Sequence Review Report 2026: Latent-transforming growth factor beta-binding protein 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LTBP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LTBP3 Biologics Sequence Review Report 2026: Latent-transforming growth factor beta-binding protein 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LTBP3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LTBP2 Biologics Sequence Review Report 2026: Latent-transforming growth factor beta-binding protein 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LTBP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LTBP1 Biologics Sequence Review Report 2026: Latent-transforming growth factor beta-binding protein 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LTBP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LTB4R2 Biologics Sequence Review Report 2026: Leukotriene B4 receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LTB4R2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LPAR4 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 4 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LPAR4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LPAR3 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 3 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LPAR3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LPAR2 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 2 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LPAR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LPAR1 Biologics Sequence Review Report 2026: Lysophosphatidic acid receptor 1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LPAR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LCOR Biologics Sequence Review Report 2026: Ligand-dependent corepressor Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of LCOR sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
L1CAM Biologics Sequence Review Report 2026: Neural cell adhesion molecule L1 Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of L1CAM sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
KITLG Biologics Sequence Review Report 2026: Kit ligand Similarity and Patent-Risk Signals
17 September 2026
A Biology Modality MCP review of KITLG sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.